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Glassy Dynamics in the Adaptive Immune Response Prevents Autoimmune Disease
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Department of Bioengineering and Department of Physics & Astronomy,
Rice University, Houston, TX 77005–1892, USA
The immune system normally protects the human host against death by infection. However,
when an immune response is mistakenly directed at self antigens, autoimmune disease can occur.
We describe a model of protein evolution to simulate the dynamics of the adaptive immune response
to antigens. Computer simulations of the dynamics of antibody evolution show that different evolu-
tionary mechanisms, namely gene segment swapping and point mutation, lead to different evolved
antibody binding affinities. Although a combination of gene segment swapping and point mutation
can yield a greater affinity to a specific antigen than point mutation alone, the antibodies so evolved
are highly cross-reactive and would cause autoimmune disease, and this is not the chosen dynam-
ics of the immune system. We suggest that in the immune system a balance has evolved between
binding affinity and specificity in the mechanism for searching the amino acid sequence space of
antibodies.
PACS numbers: 87.10.+e, 87.15.Aa, 87.17.-d, 87.23.Kg
One of the main functions of the immune system
is to generate B cells that secrete antibodies, protein
molecules that recognize and bind to antigen. The im-
mune system has evolved a hierarchical strategy to pro-
duce antibodies that combat invading pathogens [1]. The
first level is VDJ recombination, in which gene fragments
are rearranged to encode functional antibodies, produc-
ing a range of antibodies with a diversity on the order
of 1012 to 1014. Upon invasion of the body by a foreign
antigen, the second level of B cell somatic hypermutation
evolution is initiated, in which division, mutation, and
selection of B cells occurs. Those B cells that produce
antibodies that bind the antigen with higher affinities are
selected and propagated. Thus, the individual point mu-
tations of somatic hypermutation essentially perform an
optimizing local search of amino acid sequence space.
When an immune response is mistakenly directed at
self antigens, autoimmune disease occurs [1]. In most
cases, the antibody/antigen interaction is highly specific.
Sometimes, however, the antibody evolved in response
to one antigen can bind other antigens, and this phe-
nomenon is called cross-reactivity [2]. Cross-reactivity
happens when the other antigen has chemical features in
common with the original antigen and is quantified ex-
perimentally by measuring the affinity of the antibody
for the other antigen. Cross-reactivity is one mechanism
by which autoimmune disease may develop.
In this Letter, we present two major results. First,
we show how different evolutionary mechanisms influ-
ence the relaxation dynamics of an evolving population
of proteins. Specifically we study the dynamics of an-
tibody generation by the immune system in response to
pathogen invasion. These dynamics are crucial to the effi-
cacy of the immune response. The hierarchical structure
of our model protein Hamiltonian plays a critical role
in the dynamics. The hierarchical structure also distin-
guishes our model from traditional short- or long-range
spin glass energy models [3, 4]. Second, we show that
antibodies with significantly higher affinities to antigen
than those produced in a primary immune response can
be found with a biologically-plausible evolution process,
but are more cross-reactive and would greatly increase
susceptibility to autoimmune disorders. The concept of
cross-reactivity is related to that of the chaos exponent
in traditional spin glasses [5, 6], except that for cross-
reactivity we are interested in the immediate energy re-
sponse rather than in the equilibrated response of the
system to a change in the couplings. Taking our two
results together, we show that in the primary adaptive
immune response a careful balance has evolved between
specificity for and binding affinity to foreign antigen.
To express the interaction energy between antibodies
and antigen, we use the generalized NK model, a model
that captures important features of the immune response
to vaccination and disease and of protein molecular evo-
lution [7, 8, 9]. The energy of interaction for a given
protein or antibody sequence is defined in the model as
U =
M∑
i=1
U sdαi +
M∑
i>j=1
U sd−sdij +
P∑
i=1
U ci (1)
The term U sd includes interactions within a secondary
structure. Interactions between secondary structures are
essential to protein folding and function. These terms are
in U sd−sd. The total number of interactions with a typi-
cal amino acid is roughly 12, and half of these are in U sd
(2(K − 1)), and the other half in U sd−sd (D(M − 1)/N).
The term U c is the direct binding interaction between
the antibody and antigen. The number of antibody sec-
ondary structural subdomains is M = 10, and the num-
ber of antibody amino acids involved directly in the bind-
ing is known to be approximately P = 5 [8]. We define
the binding constant between antibody and antigen to
be equal to K = expa−b〈U〉 where a and b are constants
found by comparison to immunological data [9]. Thus,
2the lower the overall energy, the better the binding affin-
ity of the antibody to the given antigen. The secondary
structure energy U sd is
U sdαi =
1√
M(N −K)
N−K+1∑
j=1
σαi(aj , aj+1, · · ·, aj+K−1)
(2)
where N = 10 is the number of amino acids in a sub-
domain, and K = 4 [10] specifies the range of the local
interactions within the secondary structure. We consider
five chemically distinct amino acid classes (negative, pos-
itive, polar, hydrophobic, and other), and all subdomains
belong to one of L = 5 different types (helices, strands,
loops, turns, and others). The quenched Gaussian ran-
dom number σαi is different for each value of its argument
for a given subdomain type, αi. All of the Gaussian σ
values have zero mean and unit variance. The energy of
interaction between secondary structures i and j is
U sd−sdij =
√
2
DM(M − 1)
D∑
k=1
σkij(a
(i)
l1
, . . . , a
(i)
lK/2
;
a
(j)
lK/2+1
, . . . , a
(j)
lK
) (3)
whereD = 6 specifies the number of interactions between
secondary structures. Here σkij and the interacting amino
acids, l1, ..., lK , are selected at random for each interac-
tion i, j, k. The chemical binding energy of each antibody
amino acid to the antigen is given by U ci = σi(ai)/
√
P .
The contributing amino acid, ai, and the unit-normal
weight of the binding, σi, are chosen at random.
In our first study, we replicate the immune system
dynamics. Each protein sequence is of the length of
N ×M = 100 amino acids, corresponding to the length
of the heavy chain variable region of an antibody. Ini-
tially there are 103 sequences, as in the human immune
response [9]. Two different strategies are used in our sim-
ulations to search protein sequence space for high affinity
antibodies. The first strategy mimics the normal adap-
tive humoral immune response. It starts with the combi-
natorial joining of optimized subdomains, after which the
sequences undergo rounds of point mutation (PM) and
selection. This is a simulation of the VDJ recombination,
somatic hypermutation, and clonal selection that occurs
in B cell development [2]. We generate five optimized
subdomain pools, each composed of 300 low-energy sub-
domains, corresponding to the L = 5 types. We use three
sequences from each subdomain pool in our VDJ recom-
bination, mimicking the known diversity [9].
In our second study, we include a more powerful search
of sequence space in the antibody evolution dynamics.
VDJ recombination is used to generate an initial popu-
lation, as in the normal immune response, but in addi-
tion to somatic hypermutation, we perform gene segment
swapping (GSS) during each round of evolution and selec-
tion. GSS-type processes are used by experimentalists to
FIG. 1: Evolution of the affinity energy for the cases of point
mutation (PM) only and gene segment swapping (GSS) plus
PM as a function of the number of rounds of mutation and
selection used to evolve the population of antibodies. Energies
evolved at larger number of rounds shown in inset.
produce antibodies with binding constants ≈ 1011− 1013
l/mol [11], and exist within the natural hierarchy of evo-
lutionary events [7, 12].
In the process of GSS, a subdomain belonging to one
of the five types is replaced by another one from the
optimized subdomain pool of the same type. Each se-
quence undergoes an average of 0.5 point mutations in
each round of selection in both strategies. In GSS+PM,
each subdomain in a sequence has a probability of 0.05
of being replaced in the process of GSS. Following mu-
tation, selection occurs, and the 20% lowest energy anti-
bodies are kept and are amplified to form the population
of 103 sequences for the next round of mutation and se-
lection. The primary response is comprised of 30 rounds
of affinity maturation, corresponding to a lag phase of
approximately 10 days [9], during which B cells undergo
clonal selection in response to antigen and differentiate
into plasma cells and memory cells. The results that fol-
low are averaged over 5000 instances of the ensemble.
The average affinity of the population of antibodies
evolves during mutation and selection. The evolution of
the affinity energy under the two different strategies is
shown in Fig. 1. The GSS+PM yields sequences with a
lower energy than those from PM. The gap is due to each
of the subdomains having an energy improved from an
average to an exceptional one, ∆U ≈ 10(U sdbest−U sdavg) =
−0.8, and due to better sd-sd interactions found by GSS.
In other words, the former is a better mechanism than
the latter in searching sequence space for higher affin-
ity antibodies to the given antigen. The best binding
energy averaged over 5000 instances of the ensemble is
UG = −21.9 in the GSS+PM case and UP = −19.7 in
the PM only case at round 30, corresponding to affinities
of K = 6.7 × 107 l/mol and K = 1.6 × 106 l/mol, re-
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FIG. 2: Affinity of memory antibody sequences after a pri-
mary immune response for the two different immune system
strategies (PM and GSS+PM) to altered antigens. The bind-
ing constant is K, and the antigenic distance of the new al-
tered antigen from the original antigen is p. Cross-reactivity
ceases at larger distances in the GSS+PM case (no cross-
reactivity for p > 0.472) than in the PM only case (no cross-
reactivity for p > 0.368).
spectively. So, GSS+PM yields an affinity more than an
order of magnitude improved, which is even better than
the affinity obtained from a secondary response by PM
only [9]. That is, the multi-spin flips of GSS+PM espe-
cially accelerate the optimization of U sd−sd in amino acid
sequence space. Antibodies with a higher affinity to the
antigen work more effectively in many ways. For exam-
ple they can neutralize bacterial toxins, inhibit the infec-
tiousness of viruses, and block the adhesion of bacteria to
host cells at lower serum concentrations of antibody [2].
Based solely on Fig. 2, it is hard to understand why Dar-
winian evolution did not result in GSS+PM or any other
more efficient strategy, rather than somatic hypermuta-
tion, as the preferred strategy for B cell expansion.
A calculation of cross-reactivity, which quantifies the
specificity of the antibody, is used to compare the anti-
bodies generated by the two strategies. Thirty rounds of
primary response affinity maturation are conducted for
both PM and GSS+PM. The antigen is then changed
by p, and so each interaction parameter in the Hamilto-
nian is changed with probability p. The affinity con-
stants are calculated for the new antigen in the two
cases. As shown in Fig. 2, we find that cross-reactivity
ceases approximately ∆p = 0.10 later in the GSS+PM
case. We also find that the affinity constant, K, de-
creases exponentially with the degree of antigenic change,
i.e. the binding energy, U , increases linearly with the
change in the antigen, p. Within the region of specific
binding (K > 100 l/mol), affinity is always better in
the GSS+PM case. These cross-reactivity experiments
show that the antibodies generated by the dynamics of
GSS+PM can recognize more antigens and with higher
affinity than those given by the PM dynamics only. Such
cross reactivity has recently been observed [13]. Inter-
estingly, U(p = 1) = U(T = 0)/5, since at p = 1 the
only correlation is that αi remains unchanged 20% of the
time. The fraction p of new σ values in U sd−sd and U c
are centered around zero and negligible compared to the
original, negative evolved values. In U sd, a fraction p of
the αi are changed, and the original, evolved sequence
gives a value of roughly zero in a changed type αj . The
overall energy lost in U is, thus, proportional to p, Fig. 2
Now the question we must answer is how many pro-
tein molecules are there between p1 = 0.368 and p2 =
0.472 that can be recognized by the antibodies produced
through VDJ recombination and GSS+PM, but cannot
be recognized by the antibodies produced through VDJ
recombination and PM only. Antibodies recognize and
bind to epitope regions of an antigen, so we are inter-
ested in how many epitopes these two different classes
of antibodies are likely to recognize. We now show that
the abnormal antibodies recognize 103 times more epi-
topes than do the antibodies produced by the normal
primary immune response. We take the typical epitope
length to be B = 20 amino acids [2, 14]. In the the-
ory, the antigenic distance is defined by the chemical
composition of the epitope. The total number of pos-
sible epitopes is, therefore, 20B since there are 20 differ-
ent amino acids [15]. In Fig. 3 we show the normal-
ized number of epitopes that are at an antigenic dis-
tance of p from the native epitope of the antibody, given
by N(p) = 19iB!/[i!(B − i)!], where i = pB. This
number is N(p1)/20
B = 2 × 10−12 and N(p2)/20B =
2 × 10−9. The number of epitopes between p = 0
and p1 and the number between p1 and p2 is approx-
imately A1 ≈ 2 × 10−12 and A2 ≈ 2 × 10−9, respec-
tively, since N grows exponentially with p. In the limit
of large B, N(p2)/N(p1) ∼ exp{−B[ln(1−p2)/(1−p1)+
p1 ln 19(1/p1− 1)− p2 ln 19(1/p2− 1)]}. This ratio is 103
for 20 amino acids. The ratio varies between 160 and
4900 at the 15–25 amino acid limits of known epitope
sizes. The ratio varies by only 30% with ±10% variation
of both p values, the precision to which the generalized
NK model p values agree with experiment [9, 16].
In order to answer the question of why selection has
favored the relatively slower dynamics in the immune re-
sponse, we consider the function of the immune system
as a whole rather than just the function of a single an-
tibody binding to a single foreign antigen. The immune
system is a delicate balance of a strong response to in-
vading non-self antigens and weak or no response to self
antigens. Thus, it is very important for the antibodies
produced by the immune system to discriminate self from
non-self [17, 18, 19]. An immune system incapable of rec-
ognizing an invading pathogen and initiating a response
is an inadequate defense mechanism. On the other hand,
production of antibodies binding to self antigens results
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FIG. 3: The number of possible epitopes that are an antigenic
distance of p from another epitope. The epitopes are assumed
to be 20 amino acids in length. The plot is normalized, so that∑
p
N(p) = 2020.
in autoimmune diseases, e.g. diseases such as type I di-
abetes and rheumatoid arthritis. It might be thought
that GSS+PM would be superior dynamics, if only the
immune system were able to perform ≈ 10 rounds. How-
ever, each subsequent exposure to related antigen would
lead to another ≈ 10 rounds. After a couple such ex-
posures, GSS+PM has evolved an an unacceptably large
binding constant, which saturates after several exposures
to of the order of 1010 l/mol, whereas PM saturates at the
value of 107 l/mol. Even with PM dynamics, our model
predicts that chronic infection may lead to autoimmune
disease, a mechanism postulated to be responsible for
some fraction of rheumatic diseases, including arthritis
[20]. To resolve the significance of this mechanism, it
would be interesting to see whether the distribution of
onset times is broad, as predicted by our model.
It has been experimentally shown that cross-reactivity
can lead to autoimmune disease [1]. From Figs. 2–3, we
know that the antibodies obtained at the end of a primary
immune response can recognize a random epitope with a
length of 20 amino acids with a probability of ≈ 10−12.
It is also known that in a typical cell there are ≈ 104
proteins, each with a length of ≈ 500 amino acids [21].
Antibodies binding to proteins recognize only surface epi-
topes. The amino acids exposed on the surface of proteins
are typically part of a loop or turn, and typically 1/3 of
the loop or turn is exposed. Thus, a typical contiguous
recognition fragment length is 6–7 amino acids. Given
a typical length of 20 amino acids for the entire loop or
turn, and the typical epitope size of 20 amino acids, an
antibody will recognize roughly 3 non-contiguous regions
of length 6–7 amino acids in the protein sequence of 500
amino acids. There are approximately 5003 ≈ 108 such
epitopes. Given the 104 proteins in a cell, there will be
≈ 1012 total epitopes expressed in each cell. Thus, the
number of epitopes recognized by a typical antibody in
each cell is A1 × 1012 ≈ 1. Even taking an exceptional
protein of length 1000 amino acids, the number increases
only to 10.
This remarkable result shows that the antibodies pro-
duced by the immune system recognize on average only
their intended target. Conversely, antibodies that would
be evolved through an immune response composed of
VDJ recombination followed by a period of GSS+PM
would recognize on average A2 × 1012 ≈ 103 epitopes in
each cell. Such antibodies, while having higher affini-
ties for the intended target, would also lead to many
more instances of autoimmune disease. Such promiscu-
ous antibodies would place too large a burden on the reg-
ulatory mechanisms that eliminate the occasional aber-
rant antibody [22]. Thus, we find that selection has suc-
cessfully evolved the human immune system to generate
antibodies that recognize on average only the intended
epitope after a humoral immune response. Inclusion of
“more efficient” moves is generally excluded by the bound
A× 1012 = O(1).
[1] C. A. Janeway, P. Travers, M. Walport, and M. J. Shlom-
chik, Immunobiology (Garland Publishing, New York,
2004), 6th ed.
[2] R. A. Goldsby, T. J. Kindt, B. A. Osborne, and J. Kuby,
Immunobiology (W. H. Freeman and Company, New
York, 2002), 5th ed.
[3] K. H. Fischer and J. A. Hertz, Spin Glasses (Cambridge
University Press, New York, 1991).
[4] D. J. Gross and M. Me´zard, Nucl. Phys. B 240, 431
(1984).
[5] M. Ney-Nifle and A. P. Young, J. Phys. A 30, 5311
(1997).
[6] V. Azcoiti, E. Follana, and F. Ritort, J. Phys. A 28, 3863
(1995).
[7] D. J. Earl and M. W. Deem, Proc. Natl. Acad. Sci. USA
101, 11531 (2004).
[8] L. D. Bogarad and M. W. Deem, Proc. Natl. Acad. Sci.
USA 96, 2591 (1999).
[9] M. W. Deem and H.-Y. Lee, Phys. Rev. Lett. 91, 068101
(2003).
[10] S. Kauffman and S. Levin, J. Theor. Biol. 128, 11 (1987).
[11] R. S. et al, J. Mol. Bio. 263, 551 (1996).
[12] M. G. Kidwell and D. R. Lisch, Evolution 55, 1 (2001).
[13] P. D. Holler, L. K. Chlewicki, and D. M. Kranz, Nature
Im. 4, 55 (2003).
[14] E. T. Mun˜oz and M. W. Deem, Vaccine 23, 1142 (2004).
[15] N. A. Campbell and J. B. Reece, Biology (Benjamin
Cummings, San Francisco, 2004), 7th ed.
[16] V. Gupta, D. J. Earl, and M. W. Deem (2005), q-
bio.BM/0503030.
[17] J. K. Percus, O. E. Percus, and A. S. Perelson, Proc.
Natl. Acad. Sci. USA 90, 1691 (1993).
[18] V. Detours, H. Bersini, J. Stewart, and F. Varela, J.
Theor. Biol. 170, 401 (1994).
[19] J. Sulzer, L. van Hemmen, A. U. Newmann, and U. Behn,
Bull. Math. Biol. 55, 1133 (1993).
[20] M. Leirisalo-Repo, Curr. Opin. in Rheumatology 17, 433
5(2005).
[21] T. Tan and M. W. Deem, Physica A 350, 52 (2004).
[22] M. Larche´ and D. C. Wraith, Nature Med. 11, S69
(2005).
